Cambridge, U.K., 05 November 2024 – Cycle Pharmaceuticals announces that Duncan Kennedy is appointed Chief Financial Officer.
Duncan Kennedy brings extensive experience of the international pharmaceuticals sector to Cycle.
“I am pleased to welcome Duncan to our leadership team,” said James Harrison, Cycle’s Founder & CEO. “Duncan is a proven business leader at the highest levels. In particular, Duncan’s experience as CFO and as a business unit leader at BTG plc, brings deep knowledge and capability to our team, as we build on our momentum and seek to provide excellent products and support services to a growing number of rare disease patients.”
“I am delighted to join Cycle, a company that is helping some of the most fragile members of our community – patients born with rare diseases,” said Duncan Kennedy. “Cycle has unique strengths, and I look forward to working with the team to execute on the company’s priorities, accelerate growth and enhance value for shareholders and all stakeholders.”
Before joining Cycle, Duncan Kennedy was CFO of James Fisher and Sons plc, the London Stock Exchange listed service provider to the energy, defence and maritime sectors.
Prior to James Fisher, Duncan spent 14 years at BTG plc, the fast-growing international healthcare business, that was a FTSE 250 index constituent prior to its acquisition in 2019 by Boston Scientific for $4.2bn. Duncan held several leadership roles during his time at BTG, including Group Financial Controller, Head of the Interventional Oncology business unit, and then CFO and Board Director from 2018.
About Cycle Pharmaceuticals
Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease patient community, and the healthcare professionals and communities that support them.
Cycle focuses on rare metabolic, immunological, and neurological genetic conditions. Within neurological conditions, Cycle focuses on multiple sclerosis. Cycle’s U.S. commercial drug products are:
- NITYR® (nitisinone) Tablets (since 2017)
- SAJAZIR™ (icatibant) Injection (since 2021)
- JAVYGTOR™ (sapropterin dihydrochloride) Tablets and Powder (since 2022)
- TASCENSO ODT® (fingolimod) (since 2023)
- TIOPRONIN delayed-release tablets (since 2024)
- ORMALVI™ (dichlorphenamide) Tablets (since 2024)
Cycle is headquartered in Cambridge, U.K. and has offices in Boston, Massachusetts.
For more information, please visit www.cyclepharma.com and follow us on X, LinkedIn and Facebook.
FOR FURTHER INFORMATION PLEASE CONTACT
Marketing@cyclepharma.com
Cycle Pharmaceuticals
Tel: +44 1223 354 118